Stock Market News
Redx Pharma reaches licence agreement with French manufacturer
Drug discovery and development company Redx Pharma has signed an option and licence agreement with French high-value compound developer Deinove for its anti-infective programme aimed at the treatment of multi-drug resistant Gram-negative bacteria.
The agreement, covering Redx's novel bacterial topoisomerase inhibitor (NBTI) programme, gives Deinove a nine-month option period to assess the programme for further development, with the AIM-quoted firm receiving option fees and payments on the exercise of the option, both of which are commensurate with an anti-infective programme.
Iain Ross, Redx Pharma's executive chairman, said, "We are very pleased to have partnered our NBTI program with Deinove who are committed to the development of anti-infectives and whose team has a proven track record of bringing products to market. With their experience in this area, we hope that they can successfully progress our NBTI programme towards the clinic. We had previously indicated our commitment to progressing anti-infectives research through a collaboration in the near term and are delighted to be making this announcement on schedule."
As of 1130 GMT, shares had slipped 2.22% to 11.00p.
The agreement, covering Redx's novel bacterial topoisomerase inhibitor (NBTI) programme, gives Deinove a nine-month option period to assess the programme for further development, with the AIM-quoted firm receiving option fees and payments on the exercise of the option, both of which are commensurate with an anti-infective programme.
Iain Ross, Redx Pharma's executive chairman, said, "We are very pleased to have partnered our NBTI program with Deinove who are committed to the development of anti-infectives and whose team has a proven track record of bringing products to market. With their experience in this area, we hope that they can successfully progress our NBTI programme towards the clinic. We had previously indicated our commitment to progressing anti-infectives research through a collaboration in the near term and are delighted to be making this announcement on schedule."
As of 1130 GMT, shares had slipped 2.22% to 11.00p.
Related share prices |
---|
Redx Pharma (REDX) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price